Phaxiam Therapeutics SAPAR Phaxiam

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 51 full-time employees. The company went IPO on 2013-05-07. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.